Table 13.6h

Persistency of Discharge Regimen by Follow-up Period, 2001 to 2005

Recipients with Heart-Lung Transplants

  Year of Transplant
2001 2002 2003 2004 2005
Discharge Regimen (w/ or w/o Steroid Use) CyA+Aza At Discharge (N) 8 6 4 5 10
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 0.0% 33.3% 50.0% 60.0% 88.9%
2 Years PostTx (%) 0.0% 33.3% 25.0% - -
3 Years PostTx (%) 0.0% 33.3% 25.0% - -
CyA+MMF At Discharge (N) 7 5 3 5 3
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 42.9% 60.0% 66.7% 20.0% 100.0%
2 Years PostTx (%) 28.6% 60.0% 0.0% 20.0% -
3 Years PostTx (%) 28.6% 40.0% 0.0% - -
Tac+Aza At Discharge (N) 1 4 5 5 2
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 0.0% 100.0% 60.0% 60.0% 100.0%
2 Years PostTx (%) 0.0% 25.0% 40.0% 40.0% -
3 Years PostTx (%) 0.0% 25.0% 40.0% - -
Tac+MMF At Discharge (N) 4 4 1 11 12
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
1 Year PostTx (%) 75.0% 50.0% 0.0% 81.8% 65.6%
2 Years PostTx (%) 75.0% 0.0% 0.0% 58.2% -
3 Years PostTx (%) 75.0% 0.0% 0.0% - -
Tac+Siro At Discharge (N) - - - 1 -
At Discharge (%) - - - 100.0% -
1 Year PostTx (%) - - - 100.0% -
2 Years PostTx (%) - - - 100.0% -
3 Years PostTx (%) - - - - -


Source: OPTN/SRTR Data as of May 1, 2007.

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.